Soo Aleman - Infectious Diseases

Author Information

Soo Aleman is affiliated with the Department of Infectious Diseases at Karolinska University Hospital and the Department of Medicine Huddinge in Infectious Diseases at Karolinska Institutet, both located in Stockholm, Sweden. Her work primarily focuses on infectious diseases, with significant contributions to understanding immune responses to viral infections, particularly SARS-CoV-2 and hepatitis viruses.

Research Contributions

Soo Aleman has made substantial contributions to the field of infectious diseases, with a focus on the immune responses to vaccines and viral infections. In 2022, she published several studies on the SARS-CoV-2 virus, examining antibody responses, vaccine efficacy in immunocompromised individuals, and the role of T-cells in recognizing different viral variants. Her research also extends to hepatitis viruses, including studies on hepatitis delta and C, highlighting antiviral resistance and treatment responses. Her work is vital in informing public health strategies and improving vaccine efficacy and therapeutic interventions.

Aliases

Soo Aleman has published under various aliases, including S Aleman and S. Aleman, though her full name is Soo Aleman.

Publication and Citation Metrics

Metric	Value
Total Citation Count	9220
H-index	31
Total Paper Count	159

Publications:

Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates

DOI: 10.1002/cti2.1379

Year: 2022

Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency

DOI: 10.1007/s10875-022-01244-2

Year: 2022

Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study

DOI: 10.1016/j.dld.2022.01.047

Year: 2022

High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?

DOI: 10.1097/QAD.0000000000003135

Year: 2022

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals

DOI: 10.1016/j.medj.2022.01.001

Year: 2022

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

DOI: 10.1016/j.jhepr.2022.100462

Year: 2022

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial

DOI: 10.3324/haematol.2021.280300

Year: 2022

Novel universal SARS-CoV DNA vaccine inducing neutralizing antibodies to huCoV-19/WH01, Beta, Delta and Omicron variants and T cells to Bat-CoV

DOI: 10.21203/rs.3.rs-1276351/v1

Year: 2022

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

DOI: 10.1038/s41591-022-01700-x

Year: 2022

Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron (B.1.1.529)

DOI: 10.21203/rs.3.rs-1217466/v1

Year: 2022

Can it be prevented?

How Do Antiviral Drugs Work?

When is a Biopsy Indicated?

What is the CDCâs Role in Vaccine Development?

What Technologies are Used in Genomic and Proteomic Studies?

What is Direct Contact in Infectious Diseases?

How Effective is Handwashing in Preventing Disease Transmission?

What Are the Outcomes of Host-Pathogen Interactions?

How Can Lyme Disease be Prevented?

How Does Climate Change Influence Infectious Diseases?

Partnered Content Networks

Relevant Topics